Last updated: September 7, 2026
Linzagolix is an oral, nonpeptide GnRH receptor antagonist commercialized in Europe as Yselty. The drug is approved for moderate-to-severe symptoms associated with uterine fibroids in adult women of reproductive age. Its principal commercial distinction is flexible dosing: 100 mg once daily without hormonal add-back therapy, or 200 mg once daily with hormonal add-back therapy for patients requiring greater ovarian suppression.
The product has European regulatory approval but does not have FDA approval or an active U.S. commercial launch. Its market opportunity is therefore concentrated in Europe and selected international markets. Linzagolix competes with relugolix combination therapy, elagolix combination therapy, injectable GnRH agonists and antagonists, hormonal contraceptives, and surgical treatment.
What is the current development status of linzagolix?
Linzagolix is in the commercial phase for uterine fibroids and remains a geographically limited product rather than a global first-line therapy.
| Item |
Status |
| Active ingredient |
Linzagolix |
| Brand |
Yselty |
| Drug class |
Oral GnRH receptor antagonist |
| Initial developer |
Kissei Pharmaceutical and ObsEva |
| Current commercial partner |
Theramex |
| Main approved indication |
Moderate-to-severe symptoms associated with uterine fibroids |
| EU authorization |
Granted by the European Commission in 2022 |
| U.S. FDA status |
No approved U.S. product |
| Dosage |
100 mg once daily without add-back; 200 mg once daily with add-back |
| Primary market |
Europe |
| Biosimilar risk |
Not applicable; linzagolix is a synthetic small molecule |
| Generic risk |
Relevant after applicable patent and regulatory exclusivity expires |
The European authorization followed the PRIMROSE clinical program, which evaluated linzagolix in women with uterine fibroids. The program supported reductions in menstrual blood loss, symptom burden and uterine fibroid-related outcomes. The 100 mg dose was positioned for patients who may not require add-back therapy, while the 200 mg dose was paired with hormonal add-back treatment to mitigate hypoestrogenic effects associated with stronger ovarian suppression.
Linzagolix is administered orally and does not require the injection infrastructure associated with depot GnRH agonists. Its pharmacologic profile also permits use without add-back therapy at the lower dose, although patient selection and monitoring remain important because GnRH antagonism can reduce estradiol levels and affect bone mineral density.
What regulatory approvals does Yselty have?
The European Commission granted marketing authorization for Yselty for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age. The approved dosing structure provides two treatment options:
| Dose |
Add-back therapy |
Commercial positioning |
| 100 mg once daily |
Not required in the labeled regimen |
Lower-intensity ovarian suppression |
| 200 mg once daily |
Required |
Higher-intensity symptom control |
The European authorization is based on the balance between reduction in heavy menstrual bleeding and management of hypoestrogenic effects. The European Public Assessment Report identifies uterine fibroids as the approved indication and provides the basis for the authorized dosing and safety information. (European Medicines Agency, 2022)
Linzagolix does not have an FDA-approved New Drug Application. The absence of a U.S. approval materially reduces the product's addressable market because the United States is one of the largest pharmaceutical markets for uterine fibroid therapies.
No FDA Orange Book listing exists for an approved linzagolix product. The absence of an Orange Book listing means there is no current U.S. reference product against which an ANDA-based Paragraph IV challenge could be filed for Yselty. If a U.S. application is later approved, listed patents and regulatory exclusivity would become central to generic-entry timing. (U.S. Food and Drug Administration, 2024)
When does linzagolix lose exclusivity?
The key composition-of-matter patent family for linzagolix originated from Kissei's GnRH antagonist research program. Publicly available drug-development materials identify international patent protection, but the commercial value of individual national patents depends on claim scope, prosecution history, supplementary protection certificates and jurisdiction-specific extensions.
A definitive global loss-of-exclusivity date cannot be assigned from the European authorization alone. The practical exclusivity analysis has four components:
- Composition-of-matter patents covering linzagolix or closely related compounds.
- Formulation and dosage patents covering oral tablets and dose-specific regimens.
- Method-of-use patents covering uterine fibroids, endometriosis or treatment protocols.
- European supplementary protection certificates and pediatric extensions.
For European markets, the core patent position is likely to be more important than regulatory data exclusivity because generic competition can arise after the relevant patent and SPC barriers expire. The standard European regulatory data-exclusivity framework generally provides eight years of data protection and two additional years of market protection, with a possible one-year extension for a significant new indication under applicable rules. (European Commission, 2024)
What patent protections are most relevant?
The highest-value claims are expected to be those covering:
- Linzagolix as a chemical entity or pharmaceutically acceptable salt.
- Oral pharmaceutical compositions containing linzagolix.
- Daily doses of 100 mg and 200 mg.
- Treatment of uterine fibroids by reducing menstrual blood loss.
- Treatment protocols using linzagolix with hormonal add-back therapy.
- Long-term administration with bone-health monitoring or estrogen-progestin supplementation.
The 100 mg no-add-back regimen may create a separate commercial and patent issue from the 200 mg add-back regimen. Even if the broad chemical patent expires, a generic company could face method-of-use or formulation claims when attempting to substitute for the branded product in specific treatment settings.
There is no established public record of a major U.S. Paragraph IV dispute involving Yselty. That reflects the lack of an FDA-approved reference product rather than the absence of potential patent risk.
What is the clinical development outlook for linzagolix?
Uterine fibroids are the lead commercial indication. Linzagolix has also been studied in endometriosis, where the same mechanism can reduce estrogen-dependent pain and disease activity. Development in endometriosis could expand the product's market, but regulatory success would depend on the durability of symptom control, bone-health data and the competitive position of existing oral GnRH antagonists.
The most commercially important development questions are:
| Development issue |
Commercial implication |
| Long-term bone mineral density |
Determines duration of use and monitoring burden |
| No-add-back dosing |
Supports broader use but may limit treatment intensity |
| 200 mg plus add-back therapy |
Improves suppression but adds treatment complexity |
| Endometriosis approval |
Could materially expand the target population |
| Reimbursement decisions |
Determines uptake across European countries |
| Comparative evidence |
Needed against relugolix combination therapy and surgery |
| Fertility and treatment sequencing |
Affects use before assisted reproduction or surgery |
Linzagolix is not a biologic and does not face biosimilar development. Its future competition will come from small-molecule generics, branded oral GnRH therapies and low-cost hormonal or surgical alternatives.
How does linzagolix compare with relugolix and elagolix?
Linzagolix competes in a class where differences in dosing, add-back requirements, treatment duration and reimbursement can outweigh small pharmacologic differences.
| Product |
Brand |
Main approved use |
Administration |
Add-back approach |
Commercial position |
| Linzagolix |
Yselty |
Uterine fibroid symptoms |
Oral once daily |
100 mg without add-back; 200 mg with add-back |
European-focused |
| Relugolix |
Myfembree/Ryeqo |
Uterine fibroids and related indications, depending on market |
Oral once daily |
Fixed combination product |
Strong branded competitor |
| Elagolix |
Oriahnn/Orilissa |
Uterine fibroids or endometriosis, depending on product |
Oral daily or twice daily |
Fixed combination for some indications |
Established U.S. presence |
| Leuprolide |
Lupron Depot and generics |
Fibroids and other hormone-sensitive conditions |
Injectable depot |
Usually limited-duration use |
Established injectable alternative |
Relugolix has a major commercial advantage in markets where the combination product is reimbursed and available. Its fixed add-back formulation simplifies prescribing and may support longer treatment. Linzagolix's counter-position is dose flexibility and the possibility of using 100 mg without add-back therapy.
Linzagolix is more exposed to market-access decisions than to clinical differentiation alone. Physicians may select it when oral convenience, lower treatment complexity or a particular dose strategy is valued. Payers may favor whichever product offers the lowest total treatment cost, including add-back therapy, monitoring and subsequent surgery.
What is the commercial market opportunity for linzagolix?
The underlying uterine fibroid population is large, but the treated oral-GnRH-antagonist market is narrower. The commercially addressable group consists primarily of women with symptomatic fibroids, heavy menstrual bleeding, adequate access to specialist care and a treatment need that justifies an expensive branded oral therapy.
A scenario-based European market model is more appropriate than a revenue extrapolation from U.S. comparators because Yselty has no U.S. sales base.
| Scenario |
European treated patients by 2030 |
Net annual sales assumption |
Implied annual sales |
| Low |
25,000 |
€1,500 |
€38 million |
| Base |
60,000 |
€2,000 |
€120 million |
| High |
110,000 |
€2,500 |
€275 million |
These figures represent analytical scenarios rather than company guidance. They assume gradual reimbursement expansion, specialist prescribing and continued use in patients seeking to delay surgery. They also assume that competing products retain substantial share.
The base case requires linzagolix to secure a durable position in several major European markets, including Germany, France, Italy, Spain and the United Kingdom. The high case would require broader endometriosis adoption, strong reimbursement, expanded prescribing duration and limited generic pressure.
Revenue will be constrained by several factors:
- Uterine fibroid treatment is highly fragmented across drug therapy, surgery, uterine artery embolization and watchful waiting.
- Some patients use GnRH antagonists as a bridge to surgery rather than as chronic therapy.
- Add-back therapy increases cost and prescription complexity.
- Reimbursement differs materially between European countries.
- Relugolix and elagolix have established commercial infrastructure.
- Low-cost hormonal therapy remains an alternative for some patients.
- Patent and regulatory protection will not prevent therapeutic substitution by other branded products.
What licensing deals affect linzagolix?
ObsEva partnered with Theramex for commercialization of linzagolix in Europe and other territories. Theramex focuses on women's health products and has commercial infrastructure in contraception, menopause and reproductive health. The partnership gives Yselty access to a focused women's-health sales platform rather than requiring an independent launch organization.
Kissei has been associated with the underlying development and regional commercialization rights. The distribution of rights between Kissei, ObsEva and Theramex is territory-specific and affects economics, supply responsibility and control of future indications.
The commercial structure creates both an advantage and a limitation. Theramex can leverage an existing women's-health portfolio, but the product may receive less promotional investment than a lead product owned by a large multinational with a global gynecology franchise.
What patent litigation and generic-entry risks affect linzagolix?
No major public patent litigation involving Yselty has established a current litigation barrier to European commercialization. The most likely future disputes would involve:
- Validity of the core compound patent.
- Infringement of dose-specific treatment claims.
- Use of linzagolix with add-back therapy.
- Formulation claims covering tablet strength or release characteristics.
- National SPC validity and term.
- Generic substitution and skinny-label strategies.
Because linzagolix is a small molecule, generic companies can pursue conventional pharmaceutical equivalence pathways after relevant protections expire. Manufacturing barriers are unlikely to be decisive. The active ingredient is chemically synthesized, and tablet production does not require the specialized biologic manufacturing systems that can delay biosimilar entry.
The strongest barriers are likely to be patent claim scope, regulatory exclusivity and market access. Manufacturing complexity is a secondary barrier.
How strong is the linzagolix patent estate?
The patent estate is commercially meaningful but does not have the defensive profile of a broad biologic platform or a product with multiple independent formulation technologies.
Strengths
- Chemical-entity protection can block direct generic substitution during its term.
- Dose-specific and add-back regimens may create secondary protection.
- European SPCs can extend effective market protection beyond the basic patent term.
- The product has a differentiated 100 mg no-add-back dosing concept.
Weaknesses
- The drug is a conventional small molecule with a foreseeable generic pathway.
- Oral GnRH antagonists have multiple branded competitors.
- Method-of-use patents may be vulnerable to noninfringing labels or alternative prescribing.
- No U.S. Orange Book position currently creates a visible U.S. patent barrier.
- Product value depends heavily on reimbursement rather than patent exclusivity alone.
Overall, linzagolix has a moderate commercial patent position. The estate can support European sales through the medium term, but it is unlikely to prevent eventual generic or therapeutic competition across major markets.
What are the main generic launch scenarios?
The most likely entry sequence is jurisdictional rather than global.
Scenario one: delayed generic entry
A core compound patent and one or more SPCs remain enforceable in key European markets. Generics enter only after the remaining national barriers lapse. This scenario supports continued branded pricing but does not eliminate competition from relugolix, elagolix or surgery.
Scenario two: early generic challenge
A generic company challenges a weak secondary patent or launches after determining that the relevant compound claims do not cover its product. The challenge could reduce prices in selected countries while the brand retains share through physician familiarity and reimbursement contracts.
Scenario three: therapeutic substitution before generic entry
Relugolix combination therapy or another oral GnRH antagonist gains preferred formulary status before linzagolix loses patent protection. In this case, Yselty loses volume without a formal generic launch.
The third scenario is a material risk because branded competition can erode sales before legal exclusivity ends.
What is the five-year market projection for linzagolix?
Under a base-case model, European Yselty sales could rise gradually through 2028-2030 as reimbursement expands and clinicians adopt oral GnRH antagonist therapy for women seeking to defer surgery. A reasonable base-case range is €80 million to €150 million in annual product sales by 2030, subject to pricing, country access and treatment duration.
| Driver |
Base-case effect |
| Wider European reimbursement |
Positive |
| Endometriosis approval |
Strongly positive |
| Relugolix competition |
Negative |
| Generic entry before 2030 |
Strongly negative |
| Greater use of 100 mg without add-back |
Positive for convenience, potentially negative for price per patient |
| Long-term bone-health concerns |
Negative |
| Strong preoperative use |
Positive for patient volume, negative for treatment duration |
The product is more likely to become a mid-sized European women's-health asset than a global blockbuster. A global blockbuster outcome would require U.S. approval, a major endometriosis indication and broad reimbursement. Neither condition is currently established.
Key Takeaways
- Linzagolix is marketed in Europe as Yselty for symptomatic uterine fibroids.
- The drug is an oral GnRH antagonist with 100 mg no-add-back and 200 mg add-back dosing.
- It has no FDA approval and no current Orange Book listing.
- Its commercial rights are associated with Theramex, with development roots in ObsEva and Kissei.
- The principal patent risks involve compound, dosing, formulation and add-back claims.
- No major public Paragraph IV or Yselty patent litigation has defined the product's current position.
- The product faces strong competition from relugolix, elagolix, leuprolide and surgical treatment.
- A reasonable European 2030 sales range is €80 million to €150 million in the base case.
- Endometriosis expansion could materially improve the outlook.
- Linzagolix has moderate patent strength but limited protection against long-term therapeutic substitution.
FAQs About Linzagolix
Is linzagolix approved in the United States?
No. Linzagolix does not have an FDA-approved product or an active Orange Book listing.
Is Yselty a biologic or a generic drug?
No. Yselty contains linzagolix, a synthetic small-molecule GnRH antagonist. It is a branded pharmaceutical product and may eventually face conventional generic competition.
Does linzagolix require add-back therapy?
The approved 100 mg regimen is used without add-back therapy. The 200 mg regimen is used with hormonal add-back therapy.
Can linzagolix be used for endometriosis?
Linzagolix has been studied in endometriosis, but the commercial impact depends on the indication and territory-specific regulatory approvals.
Which company sells Yselty?
Theramex is the principal commercial partner for Yselty in Europe and related territories.
References
-
European Medicines Agency. (2022). Yselty: EPAR - Product information. https://www.ema.europa.eu/
-
European Commission. (2024). Pharmaceutical legislation and regulatory data protection in the European Union. https://health.ec.europa.eu/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
ObsEva SA. (2021). Annual report and corporate update. https://www.obseva.com/
-
Theramex. (2022). Theramex announces European commercialization of Yselty. https://www.theramex.com/
-
Kissei Pharmaceutical Co., Ltd. (2022). Corporate information and women’s health development programs. https://www.kissei.co.jp/english/
